Financial Performance - The company's operating revenue for the reporting period was CNY 202.83 million, an increase of 5.79% compared to the same period last year [4]. - The net profit attributable to shareholders decreased by 11.47% to CNY 29.35 million, while the net profit excluding non-recurring gains and losses increased by 8.40% to CNY 25.70 million [5]. - Basic earnings per share fell by 11.11% to CNY 0.32 [5]. - The weighted average return on equity (ROE) before non-recurring items was 8.44%, while the ROE after non-recurring items was 7.39% [5]. Assets and Equity - Total assets at the end of the reporting period were CNY 397.18 million, down 5.89% from the beginning of the period [5]. - The company's equity attributable to shareholders increased by 0.03% to CNY 342.75 million [5]. - The company distributed cash dividends to shareholders, which increased by 58.89% compared to the previous year, contributing to the growth in shareholder equity distribution [6]. Costs and Subsidies - The company faced increased costs due to the expansion of laboratory facilities and equipment purchases, impacting net profit [5]. - Government subsidies recognized in the current period decreased by 63.24%, affecting non-recurring profit figures [5]. Audit and Final Data - The final financial data is subject to audit and may differ from the preliminary figures reported [7].
中纺标(873122) - 2024 Q4 - 年度业绩